Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

COVIT-TRIAL, 2022 NCT04344041

hight dose vitamin D (n=130) vs. Vitamin D (n=130)

randomized controlled trial   high risk of bias

Studied treatment

high dose vitamin D3 (400,000 IU)
single oral high dose of cholecalciferol (vitamin D3) administered within 72 hours after the diagnosis of COVID-19

Control treatment

standard-dose vitamin D3 (50,000 IU)

Patients

COVID-19 mild to moderate

≥65 years, had SARS-CoV-2 infection of less than 3 days, and at least 1 COVID-19 worsening risk factor (among age ≥75 years, SpO2 ≤94%, or PaO2/FiO2 ≤300 mm Hg)

Method

open-label

9 medical centers in France

ambiguous results table for mortality with 3 analysis methods without mention of the preplanned primary analysis. Whatever, the 14-days censured cox result is not robust given the others 14 days and 28 days results (in particular the 14-days death *rate* comparison, probable preplanned primary analysis according to the published protocol)

Remark